Breaking News
Get 40% Off 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did 😎 Read how
Close

Hemostemix Inc (HEM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.0400 0.0000    0.00%
11:00:00 - Delayed Data. Currency in CAD ( Disclaimer )
Type:  Equity
Market:  Canada
  • Volume: 100,000
  • Bid/Ask: 0.0400 / 0.0450
  • Day's Range: 0.0400 - 0.0400
Hemostemix Inc 0.0400 0.0000 0.00%

Hemostemix Inc Company Profile

 
Get an in-depth profile of Hemostemix Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient’s own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Contact Information

Address 707-7th Avenue SW Suite 1150
Calgary, T2P 3H6
Canada
Phone 905-580-4170
Fax -

Top Executives

Name Age Since Title
Alan B. Lumsden - - Member of Scientific Advisory Board
York N. Hsiang - 2020 Member of Scientific Advisory Board
Peter Alan Lacey 67 2020 Independent Chairman
Loran Swanberg - 2020 Independent Director
Thomas A. Smeenk 61 2019 Co-Founder, President, CEO & Director
Norman C. W. Wong - 2017 Member of Scientific Advisory Board
Kumar L. Hari - 2017 Member of Scientific Advisory Board
Sheila Copps - 2020 Member of Board of Advisors
David H. Tsubouchi 71 2020 Member of Board of Advisors
Ronnie Allen Hershman - 2020 Independent Director
Ernst von Schwarz - 2022 Member of Scientific Advisory Board
Johannes Grillari - 2022 Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HEM Comments

Write your thoughts about Hemostemix Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Thomas Tam
Thomas Tam Apr 25, 2024 10:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$HEM's focus on autologous cell therapies holds immense potential for revolutionizing healthcare. Exciting to see the impact they can make over TSX-V by attracting long term investors.
leliani cruz
Leliani Apr 25, 2024 10:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
With a market cap exceeding $3.9M and over 87.12M outstanding shares, Hemostemix ( $HEM ) presents an intriguing investment opportunity in the rapidly evolving field of regenerative medicine.
Braxton lee
Braxton lee Apr 25, 2024 10:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
With an impressive market cap and 87.12 million outstanding shares, $HEM holds a prominent position as the most valuable penny stock on the TSXV index.
Braxton lee
Braxton lee Apr 24, 2024 10:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$HEM shines brightly as a good performer on the TSX-V index! With a trading price of $0.04 and significant trading volume, $HEM's outstanding performance is driving excitement and interest in the stock market.
Fedrick Walker
Fedrick Walker Apr 22, 2024 9:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Recent trading volumes surged to 111K, indicating a rising investor interest in $HEM activities and projects.
Steven Paul
Steven Paul Apr 22, 2024 9:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Despite an initial open of $0.05, the stock's 52-week high of $0.175 signifies considerable upside potential. With a market cap of $4.35M, Hemostemix ($HEM) operates within the smaller biotech landscape.
Fedrick Walker
Fedrick Walker Apr 18, 2024 1:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
With 87.12 million outstanding shares, $HEM possesses a sizable equity base.
Steven Paul
Steven Paul Apr 18, 2024 11:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$HEM showcases both volatility in the biotech arena, its 52-week high/low range of $0.175/$0.05 highlights the significant gains.
Fedrick Walker
Fedrick Walker Apr 16, 2024 10:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$HEM average volume of 33.15k shares, it seems like investors are sticking around for the long haul, believing in the company's vision.
Steven Paul
Steven Paul Apr 16, 2024 9:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$HEM sustains investor interest, opening at $0.055 with a 20-day average volume of 30.25k shares.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email